Forte Biosciences (FBRX) Equity Ratio (2016 - 2026)

Forte Biosciences (FBRX) has 11 years of Equity Ratio data on file, last reported at 0.63 in Q1 2026.

• Equity Ratio for Q1 2026 came in at 0.63, down 22.65% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.63 (down 22.65% YoY), and the FY2025 annual result was 0.74, down 13.57% from the prior year.
• Equity Ratio eased to 0.63 in Q1 2026 per FBRX's latest filing, from 0.74 in the prior quarter.
• Over five years, Equity Ratio peaked at 0.97 in Q1 2022 and troughed at 0.52 in Q3 2024.
• A 5-year average of 0.83 and a median of 0.87 in 2025 frame the typical range for Equity Ratio.
• The sharpest annual moves came in 2024 and 2025: Equity Ratio sank 38.16% in 2024, then surged 65.97% in 2025.
• A 5-year view of Equity Ratio shows it stood at 0.92 in 2022, then slipped by 1.99% to 0.91 in 2023, then retreated by 5.9% to 0.85 in 2024, then slipped by 13.57% to 0.74 in 2025, then declined by 15.0% to 0.63 in 2026.
• Business Quant data shows FBRX's Equity Ratio at 0.63 in Q1 2026, 0.74 in Q4 2025, and 0.87 in Q3 2025.